BTI Key Focus Areas

BTI develops innovative research capabilities and advanced biomanufacturing technologies to achieve the vision of ensuring quality processes for biomanufacturing. Modality-specific strategies are key to achieving our mission of developing Singapore's biomanufacturing sector where asset classes (proteins, cells and nucleic acids) are in various stages of maturity and development.

Proteins

BTI has focused on building strong cell-line development capabilities coupled with hybrid machine learning and metabolic flux mechanistic models for rational media and process developments. These capabilities flexibly adapt and address manufacturability of next-gen biologics (e.g. multi-specific antibodies).

Cells

BTI engages in asset and process development for therapies in accordance with cGMP and regulatory requirements. The goal is to go beyond lab-scale towards pre-GMP/GMP process development of assets.

Nucleic Acids

BTI is focusing on establishing small to mid-scale non-GMP mRNA manufacturing capabilities to facilitate the local ecosystem in swiftly developing and scaling up high-quality mRNA drug products for preclinical studies.